New drug combo trial aims to control aggressive blood cancer
NCT ID NCT02523976
Summary
This study tested adding the drug dasatinib to standard chemotherapy for adults newly diagnosed with a fast-growing type of blood cancer called Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The goal was to see if this combination was effective and tolerable for controlling the disease. The trial involved 30 patients and allowed for stem cell transplants when possible.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE,LEUKEMIA, LYMPHOID are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, 300020, China
Conditions
Explore the condition pages connected to this study.